The ability of the immune system to recognize melanoma cells is based on the presence of immunogenic antigens capable of triggering a specific immune response. A continuous search for tumor antigens, which could be used to direct the human immune system against cancer lead to the discovery of several

families of key-cancer-related molecules [3], [4], [5], [6] and [7]. Between these tyrosinase related protein 2 (TRP-2; also Selleckchem BIBF1120 known as dopachrome tautomerase; DCT) represents to date a major target of immunotherapy for melanoma. TRP-2 is a membrane-bound melanosomal enzyme involved in melanin biosynthesis also known as a melanoma differentiation antigen expressed in normal melanocytes, melanomas, normal retinal tissue and brain [8]. TRP-2 was identified by screening a tumor cDNA library with a T cell line exhibiting an in vivo antitumor activity. This finding demonstrated the immunogenicity of TRP-2 and to date several epitopes of this protein have been described to be recognized by specific cytotoxic T lymphocytes in humans. Based on these findings, TRP-2 represents a good target for immunotherapeutic treatment of melanoma [9], [10] and [11]. Although several vaccination strategies targeting TRP-2 have been developed so far [12], [13], [14] and [15], its expression in melanoma tissues is not yet fundamentally investigated. It has been reported

that TRP-2 is neural crest specific and only expressed in melanocytes, in the pigment epithelium of the retina and in the brain [8]. Of major interest is that TRP-2 has been described to Selleckchem CX-4945 be hypoxia related [16]. In this project we investigated the expression of TRP-2 in over 200 melanoma biopsies and cell cultures from primary melanomas and metastasis. Moreover, we characterized the subpopulation of melanoma cells expressing TRP-2. Trp-2 (Dct) is a marker of melanocytic lineage and in mice its expression in the bulge region of the hair follicle identifies stem cell population [17]. However, Trp-2 (Dct) is expressed throughout the melanocytic lineage including not only melanocyte stem cells, which are

c-Kit negative but also melanoblasts and differentiated melanocytes, which express c-Kit marker. Taken together our findings illustrate that TRP-2 is a melanoma differentiation antigen and not a stem cell marker. Palbociclib Furthermore, we identified an aggressive, proliferative TRP-2-negative subpopulation in primary melanoma, which significantly increases with tumor progression. Interestingly, the presence of this subpopulation in primary melanoma is associated with Breslow tumor thickness, hypoxia and indicates a less favourable tumor specific survival. This is in contradiction with the idea that TRP-2 might label the melanocyte stem cell population, while it is believed that stem cells are associated with more aggressive behaviour and less differentiation in many tumors.